The quarter missed the only clean benchmark. ArriVent reported a second-quarter net loss of $1.05 per share versus published consensus near $0.99, a roughly $0.06-per-share miss. The loss also widened to $49.9 million from $31.4 million a year earlier, driven by higher research and development and general and administrative spending (Income Statement).
| Metric | Q2 2026 | Q2 2025 | Market comparison |
|---|---|---|---|
| Net loss | $(49.9)M | $(31.4)M | — (Income Statement) |
| R&D expense | $42.3M | $27.7M | — (Income Statement) |
| G&A expense | $10.4M | $5.9M | — (Income Statement) |
| Net loss per share | $(1.05) | $(0.90) | Consensus near $(0.99) |
| Cash and equivalents | $154.7M | $45.5M at Dec. 31, 2025 | — (Balance Sheet) |
| Short-term investments | $218.4M | $267.3M at Dec. 31, 2025 | — (Balance Sheet) |
The spending increase reflects pipeline execution, not a new revenue problem. R&D rose 53% year over year in the quarter as ArriVent advanced the FURVENT and ALPACCA pivotal studies and moved ARR-217 into dose optimization. But the company remains pre-revenue in this filing, so the higher cost base flows directly into a larger loss rather than being offset by commercial sales (Income Statement; Company Progress).
The balance sheet keeps the clinical story funded for now. Cash, cash equivalents, and short-term investments totaled approximately $373.1 million at June 30, 2026, up from roughly $312.8 million at year-end despite the first-half net loss. The filing does not provide an explicit cash-runway forecast, so the exact duration cannot be confirmed from this release alone (Balance Sheet; Income Statement).
The real valuation event remains clinical, not quarterly financials. Management highlighted upcoming pivotal topline data from the 398-patient FURVENT study and initial Phase 1 data for ARR-217, but supplied no new dated readout or efficacy result in this filing. That leaves the central investment question unchanged: whether firmonertinib can beat chemotherapy on progression-free survival in EGFR exon 20 insertion disease (Company Progress; FURVENT clinical trial description).
Net read: a modest earnings miss with no offsetting new catalyst. The cash position is reassuring and the pipeline remains active, but neither changes the fact that Q2 came in below the roughly $(0.99) consensus expectation. With no new clinical data or explicit timing upgrade, the filing lands slightly worse than expected rather than materially changing the broader setup.
Read the original 8-K on SEC EDGAR ↗